Key result
Shoulder synovial sarcoma is linked to an ~83% 5-year survival rate, exceeding general literature estimates.
Why the study?
Synovial sarcoma of the shoulder is rare and limited information exists about its clinical course and prognosis.
Observational (n=14)
No
Synovial sarcoma of the shoulder has a better prognosis (83.3% 5-year survival) than expected based on general literature, behaving more like extremity than trunk sarcomas.
May indicate better prognosis for shoulder synovial sarcoma; leaves open confirmation of site-specific factors in larger series.
BACKGROUND AND OBJECTIVES: Synovial sarcoma is a rare soft tissue sarcoma with poor long-term prognosis due to late recurrence and metastasis. Synovial sarcoma arises in less than 6% from the shoulder. As a result, there is limited information in the literature about synovial sarcoma of the shoulder (SSS). METHODS: We included all patients treated for SSS at our institution between 1985 and 2013. Medical charts were retrospectively reviewed to collect demographics, information about the clinical course, and outcome. This subgroup was compared to our institution's entire synovial sarcoma patient cohort and the data in the published literature. RESULTS: SSS Patients presented most commonly with pain and a growing mass; the majority of tumors were grade 2 and measured greater than 5 cm. 43% (7) of SSS patients developed metastatic disease and 36% (5) had died at a median follow-up of 64 months (36-127); SSS 5-year survival (83.3%) was higher in our series than in the general literature (57-75%). CONCLUSIONS: We found better prognosis in patients with synovial sarcoma of the shoulder than expected based on the current literature. The clinical behavior of synovial sarcoma in the shoulder is closer to that of synovial sarcoma in the extremities than the trunk. LEVEL OF EVIDENCE: Level IV, Case Series.
No takes yet. Share an insight, caveat, or question.
Verbeek et al. (2017) conducted an observational in Synovial sarcoma of the shoulder (n=14). Synovial sarcoma of the shoulder vs. General literature (synovial sarcoma) was evaluated on 5-year survival. Patients with synovial sarcoma of the shoulder demonstrated an 83.3% 5-year survival rate, which was higher than the 57-75% rate reported in the general literature.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: